These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 31712394)

  • 1. Therapeutic Targeting of MDR1 Expression by RORγ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs.
    Wang Y; Huang Z; Chen CZ; Liu C; Evans CP; Gao AC; Zhou F; Chen HW
    Mol Cancer Ther; 2020 Feb; 19(2):364-374. PubMed ID: 31712394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
    Lombard AP; Liu C; Armstrong CM; Cucchiara V; Gu X; Lou W; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Oct; 16(10):2257-2266. PubMed ID: 28698198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming ABCB1 mediated multidrug resistance in castration resistant prostate cancer.
    Sarwar S; Morozov VM; Newcomb MA; Yan B; Brant JO; Opavsky R; Guryanova OA; Ishov AM
    Cell Death Dis; 2024 Aug; 15(8):558. PubMed ID: 39090086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the
    Lombard AP; Lou W; Armstrong CM; D'Abronzo LS; Ning S; Evans CP; Gao AC
    Mol Cancer Ther; 2021 Oct; 20(10):2061-2070. PubMed ID: 34326198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer.
    Zhu Y; Liu C; Nadiminty N; Lou W; Tummala R; Evans CP; Gao AC
    Mol Cancer Ther; 2013 Sep; 12(9):1829-36. PubMed ID: 23861346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein.
    Duran GE; Derdau V; Weitz D; Philippe N; Blankenstein J; Atzrodt J; Sémiond D; Gianolio DA; Macé S; Sikic BI
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1095-1103. PubMed ID: 29675746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
    Kato T; Mizutani K; Kameyama K; Kawakami K; Fujita Y; Nakane K; Kanimoto Y; Ehara H; Ito H; Seishima M; Deguchi T; Ito M
    Urol Oncol; 2015 Sep; 33(9):385.e15-20. PubMed ID: 26027763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M; Kashiwagi E; Yokomizo A; Takeuchi A; Dejima T; Song Y; Tatsugami K; Inokuchi J; Uchiumi T; Naito S
    Prostate; 2013 Sep; 73(12):1336-44. PubMed ID: 23775496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orphan nuclear receptor RORγ confers doxorubicin resistance in prostate cancer.
    Gao M; Guo L; Wang H; Huang J; Han F; Xiang S; Wang J
    Cell Biol Int; 2020 Oct; 44(10):2170-2176. PubMed ID: 32584473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked response to cabazitaxel in prostate cancer xenografts expressing androgen receptor variant 7 and reversion of acquired resistance by anti-androgens.
    Ylitalo EB; Thysell E; Thellenberg-Karlsson C; Lundholm M; Widmark A; Bergh A; Josefsson A; Brattsand M; Wikström P
    Prostate; 2020 Feb; 80(2):214-224. PubMed ID: 31799745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel.
    Kathawala RJ; Wang YJ; Shukla S; Zhang YK; Alqahtani S; Kaddoumi A; Ambudkar SV; Ashby CR; Chen ZS
    Chin J Cancer; 2015 Mar; 34(3):115-20. PubMed ID: 25962593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERG induces taxane resistance in castration-resistant prostate cancer.
    Galletti G; Matov A; Beltran H; Fontugne J; Miguel Mosquera J; Cheung C; MacDonald TY; Sung M; O'Toole S; Kench JG; Suk Chae S; Kimovski D; Tagawa ST; Nanus DM; Rubin MA; Horvath LG; Giannakakou P; Rickman DS
    Nat Commun; 2014 Nov; 5():5548. PubMed ID: 25420520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
    Eskra JN; Schlicht MJ; Bosland MC
    Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.
    Ríos-Colón L; Cajigas-Du Ross CK; Basu A; Elix C; Alicea-Polanco I; Sanchez TW; Radhakrishnan V; Chen CS; Casiano CA
    Oncotarget; 2017 Apr; 8(15):24915-24931. PubMed ID: 28212536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
    Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
    Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Castration-resistant prostate cancer: novel therapeutics pre- or post- taxane administration.
    Shiota M; Yokomizo A; Fujimoto N; Kuruma H; Naito S
    Curr Cancer Drug Targets; 2013 May; 13(4):444-59. PubMed ID: 23517595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.
    Lin HM; Nikolic I; Yang J; Castillo L; Deng N; Chan CL; Yeung NK; Dodson E; Elsworth B; Spielman C; Lee BY; Boyer Z; Simpson KJ; Daly RJ; Horvath LG; Swarbrick A
    Sci Rep; 2018 May; 8(1):7820. PubMed ID: 29777112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein.
    Brooks TA; Minderman H; O'Loughlin KL; Pera P; Ojima I; Baer MR; Bernacki RJ
    Mol Cancer Ther; 2003 Nov; 2(11):1195-205. PubMed ID: 14617793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.